SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Democratic gains in the midterms are driving intense debate over the market outlook, with traders concerned about possible data-center and AI regulation, tax changes, and political uncertainty. Others argue the result is already priced in and that divided government could limit policy changes, pointing to a sharp rebound in futures after the initial selloff.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Projected Democratic control of Congress is the dominant catalyst, with traders viewing the midterm losses as a major political setback for Trump and many expressing bearish sentiment on DJT amid speculation about investigations and a weakened agenda. Some argue congressional gridlock could limit policy changes, but the conversation is largely focused on the elections implications for Trump and the company.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Democratic gains in Congress are driving debate over QQQ: some traders fear tighter AI and data-center rules could weigh on the tech-heavy Nasdaq, while others see gridlock and reduced uncertainty as supportive. The community is split after a sharp selloff and rebound, with dip-buyers calling it a relief move and bears warning of further tech weakness.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

Democratic election gains, including in Texas, are driving concern that SpaceX could face greater scrutiny of Musks government ties, contracts, data-center plans, and a possible Tesla merger. Traders disagree on the impact: some expect political headwinds, while others argue the projects can proceed and view the weakness as a buying opportunity.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Traders are debating a volatile post-election reaction, with speculation that Democratic gains could lead to data-center restrictions and slow AI spending weighing on MU and other chip stocks. Bulls counter that the risk is overstated and point to strong AI-related memory demand, rising memory prices, and upbeat AMD results as reasons for optimism.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Apples warning that memory prices are rising and expected to keep climbing has renewed bullish interest in SanDisk and other memory stocks, with traders viewing it as evidence of tight supply and pricing strength. The rebound is contested, as many remain wary of the sectors sharp recent swings and question whether AI-related demand can offset memorys cyclical risks.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros blowout quarterly results and higher full-year outlook, driven by strong AI-server demand, are the main focus. Traders are upbeat about growth and the new guidance but debate whether thin margins and lingering confidence concerns justify the muted, volatile share reaction.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL swung sharply as Democratic election gains sparked fears of tighter data-center rules and slower AI infrastructure spending, weighing on semiconductor stocks. Traders debated whether the selloff was an overreaction, while chip shares rebounded with election uncertainty easing and AMD and SMCI results supporting sentiment.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is drawing attention over traders reaction to perceived Democratic gains in the elections and Elon Musks political involvement. Many fear added scrutiny of Musks companies, reduced government support, and complications for a possible SpaceX merger, while some argue EV policies could benefit Tesla or view the selloff as a buying opportunity.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracles stock-and-bond financing for its AI data-center expansion is driving debate over dilution, borrowing costs and whether future cloud revenue will generate enough cash to justify the spending. Some traders view the completed fundraising and share-price rebound as easing the overhang, while others remain concerned about debt and further downside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CVKD Stock Retail Sentiment Peaks After FDA Clears Phase 3 Path For Blood Clot Drug 

Equity

Its late-stage trial targets 120 patients globally, with results aimed at pushing for a potential NDA filing in 2029.

Why Is Cadrenal Therapeutics Stock Drawing Retail Attention Today?

The company said VLX-1005 targets a high-risk heparin complication with limited treatment options.

Matthew Szot Sells 9,933 Shares of Cadrenal Therapeutics (NASDAQ:CVKD) Stock

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD - Get Free Report) CFO Matthew Szot sold 9,933 shares of the company's stock in a transaction dated Monday, December 29th. The shares were sold at an average...

Why the underdog mindset could be your business superpower

You can catch Warrior Money on Apple Podcasts, Spotify, Amazon Music, or wherever you get your podcasts. What does it take to go from refugee kid to Marine pilot, biotech CEO, and author? On this...

Cadrenal Therapeutics, Inc.  

Cadrenal Therapeutics Expands Pipeline With Portfolio Acquisition Worth Up To $15 Million

The company said that the acquisition will significantly enhance its pipeline by adding novel assets in acute and chronic anticoagulation settings.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Bullish Sentiment

<ul class="summary-bullets"><li>Cadrenal is now planning a randomized, placebo-controlled study alongside standard anticoagulants.</li><li>The company's Phase 2 data showed over a 25% reduction in clotting, though the trial missed its primary endpoint on platelet recovery.</li><li>Cadrenal is also advancing its 12-LOX platform into areas like obesity and diabetes.</li></ul>Shares of Cadrenal Therapeutics, Inc. (CVKD) saw its retail sentiment peak to a record high late Sunday after the U.S. Food and Drug Administration (FDA) cleared the path for its blood clot drug CAD-1005 to advance into a Phase 3 trial for heparin-induced thrombocytopenia (HIT).<a href="https://stocktwits.com/symbol/CVKD">CVKD stock</a> jumped nearly 3% overnight heading into Monday. On Friday, shares fell 2% and extended losses by another 2% in extended trading.&nbsp;<h2 class="st-heading-2">CVKD Eyes Phase 3 After FDA Feedback</h2>The company said that the guidance came after its End-of-Phase 2 meeting, which was completed in March, covered protocol design, study population, dosing, background therapy, safety database, and the primary endpoint of new or worsening thrombotic events. Based on the feedback, Cadrenal will initiate a randomized, blinded, placebo-controlled Phase 3 trial evaluating CAD-1005 alongside standard anticoagulant therapy.“Building on our Phase 2 experience with CAD-1005 in HIT and now with FDA guidance for Phase 3, Cadrenal is positioned to pursue a pivotal trial for the first new therapy for HIT in more than two decades,” CEO Quang X. Pham said in a statement.&nbsp;&nbsp;In February, Cadrenal reported results from the trial, which showed over a 25% absolute reduction in thrombotic events in patients treated with CAD-1005 on top of standard anticoagulants, compared with placebo. The study did not meet its primary endpoint based on platelet count recovery, which the company said may not be an appropriate indicator for clinical benefit in HIT.Despite similar platelet recovery rates across both groups, fewer thrombotic events were observed in the CAD-1005 arm, with high event rates continuing in the placebo group. The company had earlier scheduled the End-of-Phase 2 meeting with the FDA in February and subsequently completed it in March, where it clarified a potential registrational pathway and began incorporating regulatory feedback into its Phase 3 protocol.<h2 class="st-heading-2">Cadrenal Targets 2029 NDA with Phase 3 Study</h2>Cadrenal’s Phase 3 study is expected to enroll around 120 patients across up to 50 clinical centers globally. Patients with suspected HIT will be randomized to receive CAD-1005 or placebo while continuing standard anticoagulant therapy and treated for up to 14 days during hospitalization.&nbsp;The primary endpoint will assess to see how often patients develop new blood clots, or if existing clots get worse, among those who are confirmed to have HIT, using a lab test called the Serotonin Release Assay, with at least one interim analysis planned. The company said the study is aimed at a potential New Drug Application submission in 2029.Cadrenal Expands Drug PipelineIn March, Cadrenal said it was expanding its pipeline of drugs that target the 12-lipoxygenase (12-LOX) pathway after adding more compounds to its portfolio, including some that can be taken orally. However, the company made clear that its focus remains on advancing CAD-1005 for HIT.However, the company said that early research suggests that blocking the 12-LOX pathway could have potential uses beyond HIT, including in conditions like obesity, type 2 diabetes and other inflammatory diseases. CAD-1005 is currently the only 12-LOX inhibitor currently in clinical-stage development and has received Orphan Drug and Fast Track designations from the FDA, along with orphan drug status from the European Medicines Agency.<h2 class="st-heading-2">How Do Retail Traders Feel About CVKD?</h2>On Stocktwits, retail sentiment for CVKD was ‘extremely bullish’ at a record high of 99/100 amid ‘extremely high’ message volume.CVKD stock has declined 62% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/gme-stock-ebay-deal-etsy-alternative-retail-traders/cZQAAUBRe7W">GameStop–eBay Deal Buzz Sparks Retail Backlash, With Some Floating Etsy Instead&nbsp;</a>

 In this photo illustration, the Cadrenal Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Current Price	$1.13
Prev Close	$1.04
Open	$1.05
Dividend Yield	0.00%
50-Day Moving Average	$1.12
Beta	1.00
Avg. Volume	194,861.60
PE Ratio	-0.23

52-Week High	$13.11
52-Week Low	$0.8163
Market Capitalization	$3.71M
EPS (Annual)	-$6.64
Price to Book	0.86
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

CVKD Fundamentals